E-Mail Alert

Add your e-mail address to receive forthcoming issues of this journal:

Journal Browser

Journal Browser

Special Issue "Hematopoietic Stem Cell Transplant for Blood Cancer"

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Hematology".

Deadline for manuscript submissions: 30 June 2019

Special Issue Editors

Guest Editor
Prof. Dr. Jonas Mattsson

Department of Oncology and Pathology, Karolinska Institutet, Department of Hematology, Oslo University Hospital and Clinical Immunology, Karolinska University Hospital, Huddinge, SE-141 86 Stockholm
Website | E-Mail
Interests: stem cell transplantation; immunotherapy; GVHD
Guest Editor
Prof. Dr. Andrea Bacigalupo

Hematology Department, Fondazione Policlinico Universitario Agostino Gemelli, Universita' Cattolica deI Sacro Cuore, Rome, Italy
Website | E-Mail
Interests: stem cell transplantation; immunotherapy; myeloid leukemia; myelodysplastic syndrome

Special Issue Information

Dear Colleagues,

Allogeneic hematopoietic stem cell transplantation is today a standard treatment for several hematological malignancies and non-malignant disorders. The number of allogeneic transplants is steadily increasing world-wide. This field has been driven by substantial research activity enabling both improved clinical outcome and quality of life. Conditioning therapy has been refined and today there is increased focus on a personal medicine approach with more individualized therapy. Optimizing the stem cell source and increasing donor options have also contributed to the development these last years. Lower treatment toxicity, better surveillance and improved treatments of infections have greatly decreased transplant-related mortality leading to improved overall survival. However, relapse of the underlying disease is still an area which needs improvement. There is much optimism around the new and exciting developments in immunotherapy such as CAR T cell therapy, checkpoint inhibitor and antibody-mediated therapies.

In summary, a better understanding how to further develop new tools to combat relapse and further refine the transplant procedure is necessary to offer this treatment to an increased number of patients with improved outcome and sustained quality of life.

Prof. Dr. Jonas Mattsson
Prof. Dr. Andrea Bacigalupo
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • allogeneic
  • stem cell transplantation
  • GVHD
  • Relapse
  • conditioning therapy
  • immunotherapy
  • CAR T cell
  • haplo

Published Papers

This special issue is now open for submission.
J. Clin. Med. EISSN 2077-0383 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top